This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Calendar: Key Dates for September

BOSTON ( TheStreet) -- A calendar of important, potentially stock-moving biotech events for September:

Sept. 7
Hospira (HSP) investor/analyst meeting.

Sept. 7-8
Baird 2011 Healthcare Conference

Sept. 8
FDA advisory panel meeting to review Johnson & Johnson's (JNJ) Xarelto for the prevention of strokes and blood clots in patients with atrial fibrillation.

Sept. 9
FDA advisory panel meeting to review the benefits and risks of long-term use of bisphosphonates to treat osteoporosis in light of safety concerns related to jawbone death and unusual thigh-bone fractures. Drugs to be examined include Merck's (MRK) Fosamax, Novartis' (NVS) Reclast, Warner Chilcott's (WCRX) Actonel and Roche's (RHHBY) Boniva.

Sept. 11-13
Rodman & Renshaw Global Investment Conference

Sept. 12
Delcath Systems (DCTH - Get Report) presenting data from phase II study in neuroendocrine tumors at the Cardiovascular and Interventional Radiology Society of Europe meeting.

Sept. 14
FDA advisory panel to discuss development and possible clinical trial design of products for the treatment of patients with non-metastatic castration resistant prostate cancer (CRPC) who have a rising serum level of prostate-specific antigen (PSA) despite being on androgen deprivation therapy (ADT). There are no drugs currently approved for this indication and no specific drugs will be presented or discussed. The FDA's experts will consider possible trial designs and suitable clinical endpoints to establish efficacy that would support approval of a drug for the treatment of non-metastatic CRPC after PSA progression on ADT.

Companies with possible interest in this segment of prostate cancer therapy include Dendreon (DNDN), Exelixis (EXEL), Medivation (MDVN) and Johnson & Johnson.

Sept. 17-20
51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Presentations include Dynavax's (DVAX - Get Report) Heplisav phase III results in hepatitis B prevention on Sept. 18 and updated phase I data on Sangamo BioSciences' (SGMO) experimental HIV drug SB-728.

Sept. 18-21
Heart Failure Society of America Annual Scientific Meeting. Presentations include data from a phase II "catheter" study of Aastrom Biosciences' (ASTM) Ixmyelocel-T in patients with dilated cardiomyopathy.

Sept. 19-21
UBS Global Healthcare Conference

Sept. 23-27
European Society for Medical Oncology (ESMO) Multidisciplinary Cancer Congress

Sept. 25-27
American Neurological Association Annual Meeting

Sept. 27-28
JMP Securities Healthcare Conference

Biotech events expected before the end of September:
Chelsea Therapeutics (CHTP): Complete FDA approval filing for Northera as treatment for neurogenic orthostatic hypotension.
Amarin (AMRN): Complete FDA approval filing for AMR101 for treatment of patients with high triglyceride levels.
Celsion (CLSN - Get Report): Interim analysis of phase III study of Thermodox in primary liver cancer.
Exelixis (EXEL): Top-line results of phase III study of cabozantinib in medullary thyroid cancer.
Vertex Pharmaceuticals (VRTX - Get Report): Top-line results of phase II study of VX-509 in rheumatoid arthritis.
Gilead Sciences (GILD): Top-line results from phase III "103" study of experimental Quad HIV pill versus Reyataz and Truvada.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
AMRN $2.46 6.49%
ASTM $3.10 -0.18%
CLSN $2.35 0.00%
DCTH $0.96 -0.16%
DVAX $23.42 6.48%

Markets

DOW 17,619.51 +23.16 0.13%
S&P 500 2,063.12 +5.48 0.27%
NASDAQ 4,986.8670 +28.3990 0.57%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs